Candel Therapeutics Inc. CADL
$8.08
▲ +4.90% 24H
About
Candel Therapeutics Inc. is a clinical-stage biopharmaceutical company developing viral immunotherapies designed to stimulate the immune system against solid tumors. Its lead candidate, CAN-2409, also known as aglatimagene besadenovec, is in Phase III clinical trials for prostate cancer, Phase II trials for pancreatic …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees55
TickerCADL
Statistics
Market Cap$591.9M
Revenue (TTM)—
Net Income-$38.2M
Net Margin—
EPS$-1.01
P/E-11.32
P/S—
P/B4.33
EV/EBITDA-8.14
ROE-51.2%
Dividend Yield—
Price$8.08
Data: Twelve Data · Revenue = mcap / P/S